



# SAFETY DATA SHEET



## Mirtazapine Solid Formulation



Version 7.2      Revision Date: 03/23/2020      SDS Number: 50168-00015      Date of last issue: 09/13/2019  
Date of first issue: 01/23/2015

### Storage:

P405 Store locked up.

### Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

### Other hazards

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

| Chemical name   | CAS-No.    | Concentration (% w/w) |
|---|------------|-----------------------|
| (+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine | 85650-52-8 | >= 10 - < 20          |
| Starch  | 9005-25-8  | >= 10 - < 20          |
| Silica  | 71187-19-4 | >= 1 - < 5            |

Actual concentration is withheld as a trade secret

## SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Suspected of damaging fertility. Suspected of damaging the unborn child.  
May cause damage to organs through prolonged or repeated exposure if swallowed.  
Contact with dust can cause mechanical irritation or drying of the skin.
- Protection of first-aiders : Dust contact with the eyes can lead to mechanical irritation.  
First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment

# SAFETY DATA SHEET



## Mirtazapine Solid Formulation



|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/13/2019  |
| 7.2     | 03/23/2020     | 50168-00015 | Date of first issue: 01/23/2015 |

---

Notes to physician : when the potential for exposure exists (see section 8).  
: Treat symptomatically and supportively.

---

### SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Silicon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

---

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions : Discharge into the environment must be avoided.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

### SECTION 7. HANDLING AND STORAGE

# SAFETY DATA SHEET



## Mirtazapine Solid Formulation



Version 7.2      Revision Date: 03/23/2020      SDS Number: 50168-00015      Date of last issue: 09/13/2019  
 Date of first issue: 01/23/2015

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
Store locked up.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

| Components  | CAS-No.    | Value type (Form of exposure) | Control parameters / Permissible concentration    | Basis     |
|---|------------|-------------------------------|---|-----------|
| (+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine | 85650-52-8 | TWA                           | 25 µg/m <sup>3</sup>                              | Internal  |
|   |            | Wipe limit                    | 250 µg/100 cm <sup>2</sup>                        | Internal  |
| Starch  | 9005-25-8  | TWA                           | 10 mg/m <sup>3</sup>                              | ACGIH     |
|   |            | TWA (Respirable)              | 5 mg/m <sup>3</sup>                               | NIOSH REL |
|   |            | TWA (total)                   | 10 mg/m <sup>3</sup>                              | NIOSH REL |
|   |            | TWA (total dust)              | 15 mg/m <sup>3</sup>                              | OSHA Z-1  |
|   |            | TWA (respirable fraction)     | 5 mg/m <sup>3</sup>                               | OSHA Z-1  |
| Silica  | 71187-19-4 | TWA (Dust)                    | 20 Million particles per cubic foot (Silica)      | OSHA Z-3  |
|   |            | TWA (Dust)                    | 80 mg/m <sup>3</sup> / %SiO <sub>2</sub> (Silica) | OSHA Z-3  |
|   |            | TWA                           | 6 mg/m <sup>3</sup> (Silica)                      | NIOSH REL |

## Mirtazapine Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/13/2019  |
| 7.2     | 03/23/2020     | 50168-00015 | Date of first issue: 01/23/2015 |

---

**Engineering measures** : Ensure adequate ventilation, especially in confined areas. Minimize workplace exposure concentrations. Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment). Dust formation may be relevant in the processing of this product. In addition to substance-specific OELs, general limitations of concentrations of particulates in the air at workplaces have to be considered in workplace risk assessment. Relevant limits include: OSHA PEL for Particulates Not Otherwise Regulated of 15 mg/m<sup>3</sup> - total dust, 5 mg/m<sup>3</sup> - respirable fraction; and ACGIH TWA for Particles (insoluble or poorly soluble) Not Otherwise Specified of 3 mg/m<sup>3</sup> - respirable particles, 10 mg/m<sup>3</sup> - inhalable particles.

**Personal protective equipment**

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

## Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection : Wear the following personal protective equipment:  
Safety goggles

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

# SAFETY DATA SHEET



## Mirtazapine Solid Formulation



Version 7.2      Revision Date: 03/23/2020      SDS Number: 50168-00015      Date of last issue: 09/13/2019  
Date of first issue: 01/23/2015

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

|  |   |   |
|--|---|---|
| Appearance                                       | : | powder  |
| Color  | : | No data available   |
| Odor   | : | No data available   |
| Odor Threshold                                   | : | No data available   |
| pH   | : | No data available   |
| Melting point/freezing point                     | : | No data available   |
| Initial boiling point and boiling range          | : | No data available   |
| Flash point                                      | : | Not applicable  |
| Evaporation rate                                 | : | No data available   |
| Flammability (solid, gas)                        | : | May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids)                           | : | No data available   |
| Upper explosion limit / Upper flammability limit | : | No data available   |
| Lower explosion limit / Lower flammability limit | : | No data available   |
| Vapor pressure                                   | : | No data available   |
| Relative vapor density                           | : | No data available   |
| Relative density                                 | : | No data available   |
| Density  | : | No data available   |
| Solubility(ies)<br>Water solubility              | : | No data available   |
| Partition coefficient: n-octanol/water           | : | No data available   |
| Autoignition temperature                         | : | No data available   |
| Decomposition temperature                        | : | No data available   |
| Viscosity<br>Viscosity, dynamic                  | : | No data available   |
| Viscosity, kinematic                             | : | No data available   |
| Explosive properties                             | : | Not explosive   |

# SAFETY DATA SHEET



## Mirtazapine Solid Formulation



Version 7.2      Revision Date: 03/23/2020      SDS Number: 50168-00015      Date of last issue: 09/13/2019  
Date of first issue: 01/23/2015

---

Oxidizing properties : The substance or mixture is not classified as oxidizing.  
Molecular weight : No data available  
Particle size : No data available

---

### SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.  
Chemical stability : Stable under normal conditions.  
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.  
Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.  
Incompatible materials : Oxidizing agents  
Hazardous decomposition products : No hazardous decomposition products are known.

---

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: 3,200 mg/kg  
Method: Calculation method

#### Components:

##### **(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Acute oral toxicity : LD50 (Rat): 320 - 490 mg/kg

##### **Starch:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

##### **Silica:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Remarks: Based on data from similar materials

---





## Mirtazapine Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/13/2019  |
| 7.2     | 03/23/2020     | 50168-00015 | Date of first issue: 01/23/2015 |

---

Test system: mammalian cells

Result: negative

Test Type: sister chromatid exchange assay

Test system: mammalian cells

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Rat  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

**Starch:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

**Silica:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

**Carcinogenicity**

Not classified based on available information.

**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Species : Mouse  
Application Route : Oral  
Exposure time : 18 month(s)  
LOAEL : 200 mg/kg body weight  
Result : equivocal  
Target Organs : Liver

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
LOAEL : 20 mg/kg body weight  
Result : equivocal  
Target Organs : Liver, Thyroid

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

## Mirtazapine Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/13/2019  |
| 7.2     | 03/23/2020     | 50168-00015 | Date of first issue: 01/23/2015 |

---

**Reproductive toxicity**

Suspected of damaging fertility. Suspected of damaging the unborn child.

**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Effects on fertility : Test Type: Fertility/early embryonic development  
 Species: Rat  
 Application Route: Oral  
 Fertility: LOAEL: 15 mg/kg body weight  
 Symptoms: Effect on estrous cycle, Increase of early resorptions.  
 Result: Animal testing did not show any effects on fertility., Embryotoxic effects and adverse effects on the offspring were detected.

Effects on fetal development : Test Type: Development  
 Species: Rat  
 Application Route: Oral  
 Developmental Toxicity: LOAEL: 100 mg/kg body weight  
 Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.

Test Type: Development  
 Species: Rabbit  
 Application Route: Oral  
 Developmental Toxicity: NOAEL: 40 mg/kg body weight  
 Result: No adverse effects., No teratogenic effects.

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

**STOT-single exposure**

Not classified based on available information.

**STOT-repeated exposure**

May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.

**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Routes of exposure : Ingestion  
 Target Organs : Nervous system  
 Assessment : May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Species : Rat

## Mirtazapine Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/13/2019  |
| 7.2     | 03/23/2020     | 50168-00015 | Date of first issue: 01/23/2015 |

---

LOAEL : 120 mg/kg  
 Application Route : Oral  
 Exposure time : 13 Weeks  
 Target Organs : Nervous system

Species : Dog  
 LOAEL : 15 mg/kg  
 Application Route : Oral  
 Exposure time : 52 Weeks  
 Target Organs : Nervous system  
 Symptoms : Tremors

Species : Dog  
 LOAEL : 20 mg/kg  
 Application Route : Oral  
 Exposure time : 13 Weeks  
 Target Organs : Nervous system, Testis  
 Symptoms : Tremors

**Starch:**

Species : Rat  
 NOAEL : >= 2,000 mg/kg  
 Application Route : Skin contact  
 Exposure time : 28 Days  
 Method : OECD Test Guideline 410

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Ingestion : Symptoms: Drowsiness, constipation, dry mouth, asthenia, Dizziness, Disorientation

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 6.92 mg/l  
 Exposure time: 96 h  
 Method: FDA 4.11

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 19.5 mg/l  
 aquatic invertebrates : Exposure time: 48 h

Toxicity to algae/aquatic : EC50 (Pseudokirchneriella subcapitata (green algae)): 5.7  
 plants : mg/l  
 Exposure time: 72 h

## Mirtazapine Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/13/2019  |
| 7.2     | 03/23/2020     | 50168-00015 | Date of first issue: 01/23/2015 |

---

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 3.2 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 3.6 mg/l  
Exposure time: 31 d  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.32 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50 (Natural microorganism): > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC (Natural microorganism): &lt; 100 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition

Method: OECD Test Guideline 209

**Silica:**

Toxicity to fish : LC50 (Brachydanio rerio (zebrafish)): > 10,000 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants : EC50: > 10,000 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

**Persistence and degradability**

No data available

**Bioaccumulative potential****Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Bioaccumulation : Species: Oncorhynchus mykiss (rainbow trout)  
Bioconcentration factor (BCF): 334  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 2.78

# SAFETY DATA SHEET



## Mirtazapine Solid Formulation



Version 7.2      Revision Date: 03/23/2020      SDS Number: 50168-00015      Date of last issue: 09/13/2019  
Date of first issue: 01/23/2015

---

### Mobility in soil

#### Components:

**(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Distribution among environmental compartments : log K<sub>oc</sub>: 4.48

#### **Other adverse effects**

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### **Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14. TRANSPORT INFORMATION

### **International Regulations**

#### **UNRTDG**

Not regulated as a dangerous good

#### **IATA-DGR**

Not regulated as a dangerous good

#### **IMDG-Code**

Not regulated as a dangerous good

#### **Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

#### **Domestic regulation**

#### **49 CFR**

Not regulated as a dangerous good

---

## SECTION 15. REGULATORY INFORMATION

### **EPCRA - Emergency Planning and Community Right-to-Know**

#### **CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

#### **SARA 304 Extremely Hazardous Substances Reportable Quantity**

This material does not contain any components with a section 304 EHS RQ.

#### **SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**

This material does not contain any components with a section 302 EHS TPQ.

#### **SARA 311/312 Hazards**

: Combustible dust  
Reproductive toxicity  
Specific target organ toxicity (single or repeated exposure)

---

# SAFETY DATA SHEET



## Mirtazapine Solid Formulation



Version 7.2      Revision Date: 03/23/2020      SDS Number: 50168-00015      Date of last issue: 09/13/2019  
Date of first issue: 01/23/2015

**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

### US State Regulations

#### Pennsylvania Right To Know

|   |            |
|---|------------|
| D-Glucose, 4-O-.beta.-D-galactopyranosyl-, monohydrate                            | 64044-51-5 |
| Starch  | 9005-25-8  |
| (+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine | 85650-52-8 |

#### California Permissible Exposure Limits for Chemical Contaminants

|        |            |
|--------|------------|
| Starch | 9005-25-8  |
| Silica | 71187-19-4 |


#### The ingredients of this product are reported in the following inventories:

|       |                  |
|-------|------------------|
| AICS  | : not determined |
| DSL   | : not determined |
| IECSC | : not determined |

## SECTION 16. OTHER INFORMATION

### Further information

#### NFPA 704:



#### HMIS® IV:

|                 |   |   |
|-----------------|---|---|
| HEALTH          | * | 2 |
| FLAMMABILITY    |   | 3 |
| PHYSICAL HAZARD |   | 0 |

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

#### Full text of other abbreviations

|           |  |
|-----------|--|
| ACGIH     | : USA. ACGIH Threshold Limit Values (TLV)  |
| NIOSH REL | : USA. NIOSH Recommended Exposure Limits   |
| OSHA Z-1  | : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants |

# SAFETY DATA SHEET



## Mirtazapine Solid Formulation



|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/13/2019  |
| 7.2     | 03/23/2020     | 50168-00015 | Date of first issue: 01/23/2015 |

OSHA Z-3 : USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts  
ACGIH / TWA : 8-hour, time-weighted average  
NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek  
OSHA Z-1 / TWA : 8-hour time weighted average  
OSHA Z-3 / TWA : 8-hour time weighted average

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 03/23/2020

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified

# SAFETY DATA SHEET



## Mirtazapine Solid Formulation



|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/13/2019  |
| 7.2     | 03/23/2020     | 50168-00015 | Date of first issue: 01/23/2015 |

---

in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8